Pharmaceuticals News and Research

RSS

CrystalGenomics raises KRW 3 billion in private placement

CrystalGenomics, Inc., a clinical stage biopharmaceutical company headquartered in Korea, has just announced that it has successfully raised KRW 3 Billion (USD 2.6 Million) in a private placement to the Korea Seoul Life Science Fund.

13 Jan 2012

ISU receives U.S. patent for phytol-derived adjuvant

While conducting research on cancer, Swapan Ghosh and a team of graduate and doctoral students discovered a phytol-derived adjuvant. That adjuvant formula just became U.S. Patent No. 8,088,395.

13 Jan 2012

GC-Rise presents at J.P. Morgan's 30th annual Healthcare Conference

GC-Rise Pharmaceutical Co. Ltd, in which European healthcare venture capital firm INVENTAGES holds a majority stake, has debuted at J.P. Morgan's 30th annual Healthcare Conference in the United States.

13 Jan 2012

Chlorophyll in green vegetables offers protection against cancer

A recent study at Oregon State University found that the chlorophyll in green vegetables offers protection against cancer when tested against the modest carcinogen exposure levels most likely to be found in the environment.

13 Jan 2012

Kedem commences development of Gleevec to treat CML in children and adults

Kedem Pharmaceuticals Inc., a specialty pharmaceutical company with focus on sublingual drug delivery system is pleased to announce that has initiated the development of Gleevec.

12 Jan 2012

Sangart commences MP4CO Phase 1b study in sickle cell disease

Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 1b study designed to evaluate the safety of MP4CO treatment in patients with sickle cell disease.

12 Jan 2012

Ocular drug delivery: DSM awarded membership in PANOPTES EU Funded Consortium

DSM, a global leader in biomedical materials sciences, today announced that it is contributing proprietary knowledge in the preparation of tailored amino acid-based polymers and offering use of processing facilities that will produce an innovative step change in the sustained delivery of drug molecules. The PANOPTES consortium’s goal is to research and develop novel drug delivery technology for the posterior eye segment. This partnership further validates the innovative properties of DSM’s polyesteramide (PEA) biomaterials as a superior drug delivery technology.

12 Jan 2012

Trends in compulsory licensing of pharmaceuticals since Doha Declaration

In this PLoS Medicine research article, Reed Beall and Randall Kuhn of the Josef Korbel School of International Studies at the University of Denver provide an analysis of trends in compulsory licensing (CL) of pharmaceuticals since the Doha Declaration.

12 Jan 2012

Caltech researchers devise new method to make complex molecules

A team of researchers at the California Institute of Technology (Caltech) has devised a new method for making complex molecules. The reaction they have come up with should enable chemists to synthesize new varieties of a whole subclass of organic compounds called nitrogen-containing heterocycles, thus opening up new avenues for the development of novel pharmaceuticals and natural products ranging from chemotherapeutic compounds to bioactive plant materials such as morphine.

12 Jan 2012

Amarantus receives U.S. patent titled, 'Dopaminergic Neuronal Survival-Promoting Factors and Uses Thereof'

Amarantus BioSciences, Inc., a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, today announced U.S. Patent Number 8,084,425 has been issued for MANF entitled, Dopaminergic Neuronal Survival-Promoting Factors and Uses Thereof.

12 Jan 2012

USPTO issues patent to Unigene's peptide-based therapeutics for obesity

Unigene Laboratories, Inc., a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that it had been granted U.S. Patent No. 8,076,291 from the United States Patent and Trademark Office.

11 Jan 2012

Nicotine patches may help individuals with early memory loss

Star Scientific, Inc. - A study released in the January 9th issue of the Journal of Neurology suggests that nicotine patches may help individuals with early memory loss.

11 Jan 2012

Spherix completes SPX-106 28-day rat toxicology study

Spherix Incorporated – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today reported the successful completion of its 28-day rat toxicology study of its drug candidate, SPX-106.

11 Jan 2012

$Merrimack commences MM-151 Phase 1 trial in refractory advanced solid tumors$

Merrimack commences MM-151 Phase 1 trial in refractory advanced solid tumors

Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.

11 Jan 2012

Arena agrees to sell 9,953,250 shares of common stock

Arena Pharmaceuticals, Inc. announced today that it has agreed to sell 9,953,250 shares of its common stock, at a price of $1.65775 per share, and approximately 9,953 shares of its Series D Convertible Preferred Stock, at a price of $1,657.75 per share, in a registered direct public offering to entities affiliated with Deerfield Management, a healthcare investment organization.

11 Jan 2012

Regular aspirin may not be good for all: Study

Researchers suggest that healthy individuals who take aspirin to prevent a heart attack or stroke could be doing more harm than good. An analysis of more than 100,000 patients, published in Archives of Internal Medicine, concluded the risk of internal bleeding was too high. The UK-led study said only people with a history of heart problems or stroke should take the tablets. Experts however added that any decision should be made with a doctor.

11 Jan 2012

Oramed files provisional patent application with USPTO for combination diabetes therapy

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has filed a provisional patent application with the United States Patent and Trademark Office for a combination therapy of its lead compound, ORMD-0801 in combination with its oral exenatide formulation, ORMD-0901. There is no such approved combination product available on the market today.

11 Jan 2012

UCSF, Sanofi enter $3.1 million collaboration to identify diabetes drug targets

The University of California, San Francisco has signed an alliance with international pharmaceutical company Sanofi to share expertise in diabetes research and identify drug targets that could lead to new therapies for both type 1 and type 2 diabetes.

11 Jan 2012

Erlotinib better for treatment of non-small cell lung cancers

Researchers at Johns Hopkins have shown that DNA changes in a gene that drives the growth of a form of lung cancer can make the cancer's cells resistant to cancer drugs.

11 Jan 2012

Foundation Medicine, Sanofi enter strategic collaboration for cancer genome analysis

Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genome analysis to routine clinical care, today announced the initiation of a strategic collaboration with Sanofi.

11 Jan 2012